(Q35552714)

8 August 2017

title

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents (English)

1 reference

8 August 2017

Kenneth C Anderson

1 reference

8 August 2017

Paul G Richardson

1 reference

8 August 2017

Teru Hideshima

1 reference

8 August 2017

Constantine S Mitsiades

object named as

Constantine S Mitsiades

1 reference

8 August 2017

Steffen Klippel

1 reference

8 August 2017

Jana Jakubikova

1 reference

8 August 2017

Merav Leiba

1 reference

8 August 2017

Yu-Tzu Tai

1 reference

8 August 2017

Adi Leiba

1 reference

8 August 2017

Mark Pines

1 reference

8 August 2017

Arnon Nagler

1 reference

8 August 2017

language of work or name

English

0 references

publication date

26 April 2012

1 reference

British Journal of Haematology

8 August 2017

published in

1 reference

8 August 2017

volume

157

1 reference

8 August 2017

1 reference

8 August 2017

page(s)

718-731

1 reference

Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Inhibition of pancreatic stellate cell activation by halofuginone prevents pancreatic xenograft tumor development

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

JNK signaling in apoptosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: a novel target for treatment?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Involvement of ERK signaling in halofuginone-driven inhibition of fibroblast ability to contract collagen lattices.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model--an MRI study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Advances in biology of multiple myeloma: clinical applications

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

MEKK1/JNK signaling stabilizes and activates p53.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Halofuginone: a novel antifibrotic therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Halofuginone: a potent inhibitor of critical steps in angiogenesis progression

27 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Apoptosis: a review of programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Growth inhibition of prostate cancer xenografts by halofuginone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

The IARC TP53 database: new online mutation analysis and recommendations to users

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Signal transduction by tumor necrosis factor mediated by JNK protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

5-fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09120.X

Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414398

Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone

26 September 2018

1 reference

12 December 2020

Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone

1 reference

12 December 2020

Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone

1 reference

12 December 2020

Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect

1 reference

12 December 2020

Halofuginone inhibits neointimal formation of cultured rat aorta in a concentration-dependent fashion in vitro

1 reference

12 December 2020

10.1111/J.1365-2141.2012.09120.X

Identifiers

DOI

1 reference

8 August 2017

1 reference

8 August 2017

1 reference